Trial
NCT06961370
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Geographic Atrophy
Intervention
RO7669330
Why stopped
The study was terminated prematurely by the Sponsor due to observation of dose-limiting adverse events meeting the protocol-defined stopping criteria.
Provenance
Dataset: 2026-08-14 • Source: ClinicalTrials.gov API v2 • Last update: 2026-08-10